$24.74
1.56% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Arvinas, Inc. Stock price

$24.74
-1.02 3.96% 1M
-16.59 40.14% 6M
-16.42 39.89% YTD
+4.34 21.27% 1Y
-62.44 71.62% 3Y
+1.99 8.75% 5Y
+8.69 54.14% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.38 1.56%
ISIN
US04335A1051
Symbol
ARVN
Sector
Industry

Key metrics

Market capitalization $1.67b
Enterprise Value $440.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.72
P/S ratio (TTM) P/S ratio 17.92
P/B ratio (TTM) P/B ratio 2.78
Revenue growth (TTM) Revenue growth -39.92%
Revenue (TTM) Revenue $93.30m
EBIT (operating result TTM) EBIT $-371.00m
Free Cash Flow (TTM) Free Cash Flow $-217.10m
Cash position $1.23b
EPS (TTM) EPS $-5.17
P/E forward negative
P/S forward 7.55
EV/Sales forward 1.99
Short interest 19.55%
Show more

Is Arvinas, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Arvinas, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Arvinas, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Arvinas, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Arvinas, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
93 93
40% 40%
100%
- Direct Costs 6.80 6.80
9% 9%
7%
87 87
41% 41%
93%
- Selling and Administrative Expenses 92 92
30% 30%
98%
- Research and Development Expense 359 359
4% 4%
385%
-364 -364
22% 22%
-390%
- Depreciation and Amortization 6.80 6.80
9% 9%
7%
EBIT (Operating Income) EBIT -371 -371
22% 22%
-398%
Net Profit -323 -323
9% 9%
-347%

In millions USD.

Don't miss a Thing! We will send you all news about Arvinas, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arvinas, Inc. Stock News

Neutral
GlobeNewsWire
30 days ago
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
Neutral
Seeking Alpha
2 months ago
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt raises, warranting a sell. HubSpot faces volatility post-Google acquisition plans, while Grifols considers privatization amid debt concerns and shareholder issues.
Neutral
GlobeNewsWire
3 months ago
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.
More Arvinas, Inc. News

Company Profile

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.

Head office United States
CEO John Houston
Employees 445
Founded 2013
Website www.arvinas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today